Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage I
Non-small Cell Lung Cancer Stage II
Non-small Cell Lung Cancer Stage III

Interventions

DEVICE: AVENIO ctDNA Surveillance Kit
DRUG: Durvalumab
DRUG: Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy

Sponsor

Stanford University

Collaborators

[object Object]